The spasticity landscape offers opportunities with over 10 companies and 12 pipeline drugs in development. Key prospects lie in novel therapies like Motric Bio's MTR-601 and Ipsen's IPN10200. Focused ...
Sativex, a cannabis-based spray for MS spasticity, was bought by CNX Therapeutics. It's used as an add-on therapy in Europe ...
Sativex is indicated for symptom improvement in adult patients with moderate to severe spasticity. Inflexion portfolio company CNX Therapeutics has acquired the global Sativex business from Jazz ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback